Alumis Presents Envudeucitinib Data Showing Complete Skin Clearance in 54% of Patients at 48 Weeks

• Alumis plans to submit a new drug application for envudeucitinib in plaque psoriasis in the fourth quarter of 2026.
• A PDUFA decision is anticipated in the fourth quarter of 2027.
• Continuous envudeucitinib treatment achieved 54% complete skin clearance at week 48; 75% achieved at least 90% improvement.
• Serious adverse events occurred in 3.2% of patients through 48 weeks; adverse events led to discontinuation in 3%.
• A Phase 2 biomarker trial of A-005, a CNS-penetrant TYK2 inhibitor, is planned for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.